Financing channel feed – Endpoints News

Financing channel feed

Armed with Langer tech and $50M, Verseau hails new checkpoint drugs unleashing macrophages against cancer

6 years ago

Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there

6 years ago

Sofinnova Partners builds stacks [on stacks, on stacks] as fund breaks past $2B mark

6 years ago

Sean Parker helps create a CRISPRed cell therapy 2.0 play — and he’s got a high-profile set of leaders on the team

6 years ago

San Diego upstart debuts discovery engine that puts a twist to protein degradation

6 years ago

Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding

6 years ago

Floating in stormy seas, RTW seeks $350M for new London-listed venture fund

6 years ago

Cyteir nets $40M for rad synthetic lethality platform — throwing another monkey wrench at cell repair

6 years ago

Woodford fired from flagship fund — which won't reopen after all

6 years ago

Boehringer Ingelheim-backed Abalos tosses hat into packed oncolytic virus ring

6 years ago

Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles

6 years ago

ARCH, SoftBank-backed Vir Biotechnology underwhelms with $143 million IPO

6 years ago

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

6 years ago

Wall Street trims cancer drug developer BioNTech's unicorn valuation

6 years ago

Another one of Neil Woodford's portfolio companies escapes as UK biotech execs flee a collapse of faith

6 years ago

'We're ripe': Cygnal draws the curtain on Flagship's latest bet on exoneural biology — and $65M in cash

6 years ago

We’ll see this week if the public markets’ love affair with biotech unicorns is still running hot — or not

6 years ago

Antibody research graduates from a top Oxford lab into the biotech world — with $34M to fund R&D work

6 years ago

Ophthalmology biotech upstart is asking investors to bet $85M-plus on their late-stage rival to Restasis and Xiidra

6 years ago

Aeovian Pharmaceuticals brings in $37 million in mTOR play

6 years ago

Regeneron doubles down on partner Adicet's gamma delta T cell tech in $80M financing

6 years ago

ADC Therapeutics isn't going public in the US after all, while three other biotech IPOs bring in $319M

6 years ago

New norm? Three biotechs pencil in $100M IPOs

6 years ago

CRISPR pioneer Feng Zhang's upstart biotech seeks $100M-plus IPO for preclinical base editing work

6 years ago

First page Previous page 107 108 109110111 112 113 Next page Last page